IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson’s Disease
Gothenburg, Sweden, December 23, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company focused on discovering and developing new treatments for Parkinson’s disease, has received regulatory and ethical approvals for a Phase Ib study of IRL757 to assess safety, tolerability, and signal finding in patients with Parkinson’s disease who experience apathy. The study will be conducted at 16 sites across four European countries and is fully funded by IRLAB’s development collaborator, the McQuade Center for Strategic Research and Development, LLC (MSRD) –an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
Q&A session with Kristina Torfgård, CEO and Nicholas Waters, EVP, Head of R&D, at Redeye Technology & Life Science Day
Kristina Torfgård, CEO, and Nicholas Waters, EVP, Head of R&D, participated in the Redeye Technology & Life Science Day on December 3, 2025. https://www.redeye.se/video/event-presentation/1130614/irlab-therapeuti%E2%80%A6-2025-october-15?embed
Read More >